NLS senzagen

The company announces the launch of GARD skin Medical Device – a new test to assess whether medical devices can cause skin allergies. Regulatory changes are already underway in the market, which will mean increased requirements for product safety. The launch will take place at the Eurotox congress in Helsinki on September 8-11, 2019. The […]

The company’s Board has appointed Axel Sjöblad as the new CEO starting June 17, 2019. Sjöblad most recently held the position as CEO of BioGaia and replaces Anki Malmborg Hager, who after five years as CEO, is nominated to become a member of the company’s board. “We are pleased to welcome Axel Sjöblad as CEO […]

The company has signed a global licensing agreement with the contract research organization Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD test to its clients. GARD is a genome-based test that gives the customers safety information whether chemical substances are at risk of causing allergies in humans. Eurofins BioPharma Product Testing […]

SenzaGen CEO Anki Malmborg Hager gives her point of view on the key factors of taking research from spin-off to success. After two decades of running pharmaceutical and biotech companies, what has it been like to go from research to commercialization and what has been the key to success? “I have realized that one crucial […]

To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California. SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins, for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an IPO in 2017. Senzagen, a […]